INTRODUCTION
'Protein glycosylation' describes the co-translational linkage and modification of oligosaccharide moieties on newly synthesized proteins. This complex metabolic process, which has been found in nearly all forms of life from bacteria to man, comprises one of the most widespread and variable forms of protein modifications. Owing to their structural variability, glycans are carriers of a code that is much more complex compared with nucleic acids and proteins. Glycoproteins play an important role in many biological processes such as growth, differentiation, organ development, signal transduction and immunologic defence, but are also involved in pathologic processes like tumour progression (1, 2) . The N-and O-glycosylation machinery is addicted to an interaction of a bulk of proteins located in the cytosol, endoplasmic reticulum and the Golgi apparatus. Inborn errors in the glycosylation process in man are termed 'congenital disorders of glycosylation' (CDG). They comprise a rapidly expanding group of autosomal recessive inherited metabolic diseases, presenting mostly with a multisystemic phenotype combined with severe neurological impairment. In recent years, not only defects in distinct glycosyltransferases, glycosidases or nucleotide-sugar transporters have been identified, but also deficiencies in the supply of products or in the maintenance of a correct pH value, all necessary for the proper proceeding of protein glycosylation, have been described (3) (4) (5) . Furthermore, several defects in different subunits of the conserved oligomeric Golgi (COG) complex have been identified (3) . The COG complex is a hetero-octameric protein complex † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. * To whom correspondence should be addressed. Tel: +49 6221562881; Fax: +49 6221565907; Email: christian.koerner@med.uni-heidelberg.de # The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org (6 -9) in the cytosol which is associated with the Golgi apparatus and is required for proper sorting and glycosylation of Golgi-resident enzymes and secreted proteins. Thereby, it is involved in the retrograde transport by COPI vesicles and assumes a role as tethering factor for initial interactions of vesicles with the target membrane (9) (10) (11) . Recent studies on the COG complex structure in CDG patients let assume a subunit interaction of COG2 -COG4 and COG5 -COG7 which form lobes A and B, respectively, that are connected by COG1 and COG8 (6, 9) . Dysfunction of the COG complex leads to a generalized hypoglycosylation in the cells ending up in a severe clinical phenotype of the affected patients. Since 2004 deficiencies in subunits COG7 (12) , COG1 (13) , COG8 (14, 15) , COG4 (7) and COG5 (8) of the hetero-octameric COG complex have been shown to lead to its malfunction and subsequently to hypoglycosylation of glycoproteins and therefore to CDG. Here, we present a new type of the CDG by identification of the molecular defect in a patient with deficiency of subunit 6 of the COG complex.
RESULTS

Case report
The index patient was the fourth child of healthy nonconsanguineous parents of Turkish origin. The family history included two other children that died in the perinatal period (one shortly after delivery and the other at 5 weeks of age) with signs of an increased bleeding tendency. Pregnancy and delivery of the female patient were uncomplicated and at term. The patient suffered from intractable focal seizures, vomiting and loss of consciousness due to intracranial bleedings. Biochemical investigations revealed a normal level for albumin and mildly elevated values for lactate, aspartate aminotransferase and creatine kinase. Metabolic investigations revealed cholestasis and subsequent vitamin K deficiency, explaining in part her intracranial bleedings. The patient died due to brain oedema at 5 weeks of age. Since the clinical phenotype of the patient was suspect for a CDG syndrome, initial CDG diagnosis was established by isoelectric focusing (IEF) of the patient's serum transferrin.
Analyses of serum transferrin, a-1-antitrypsin and apolipoprotein CIII Diagnosis of CDG was performed by IEF and western blotting of serum transferrin. The IEF pattern from the CDG-IIL patient showed the presence of transferrin molecules with four, three, two, one or no sialic acid residues (Fig. 1A) , typical for CDG-type II deficiencies. The partial loss of sugar residues of N-glycans in CDG-IIL was demonstrated by a smear in western blotting of serum transferrin (Fig. 1B ) in contrast to a control or a CDG-Ia patient, who showed defined additional bands with faster mobility due to the complete loss of either one or two glycan chains, typical for CDG-I deficiencies. To confirm CDG in the patient, IEF of an alternative glycoprotein, plasma a-1-antitrypsin, was performed. Human plasma a-1-antitrypsin is normally glycosylated at amino acid residues 46, 83 and 247. Owing to the combinations of tri-and di-antennary-complex-type oligosaccharides and shortened isoforms of the protein, a pattern of seven bands in the IEF analysis of a-1-antitrypsin in healthy controls (Fig. 1C, lane  1) is detectable. For CDG, it has been shown that additional bands with a cathodal shift appear, the number and the size of which depend on the corresponding type of CDG (Fig. 1C,  lanes 2 and 3) . To further investigate, if the patient's defect also has an impact on the biosynthesis of core 1 mucin type O-glycans, IEF of the corresponding marker protein apolipoprotein CIII (ApoCIII) derived from sera of the patient and a control was performed. This method allows the quantitative determination of the three ApoCIII isoforms (ApoCIII 0 -2 ), either with two sialic acid residues in 2,3 and 2,6 orientation (ApoCIII 2 ), with one sialic acid residue in 2,3 or 2,6 orientation (ApoCIII 1 ) or with no sialic acid residue (ApoCIII 0 ). In the case of the patient, an increased ApoCIII 0 pattern was detected. This difference in charge could be induced by a hypoglycosylation of the glycan or a mutation in the backbone of the protein. To find out, treatment of the patient's and a control serum with a 2,3-sialidase and an unspecific cutting sialidase was accomplished. Sialidase treatment with the 2,3-sialidase revealed disappearance of the fully sialylated ApoCIII 2 form in the case of the control and the patient. Where in the control, the ratio of ApoCIII 1 to ApoCIII 0 was balanced, the patient showed minor ApoCIII 1 . Incubation with the unspecific cutting sialidase led to the emergence of ApoCIII 0 by deprivation of ApoCIII 1 and ApoCIII 2 forms in control and the patient. These results indicated a combined N-and O-glycosylation deficiency in the patient.
Lectin staining with peanut agglutinin
Staining of control and patient's fibroblasts with biotinylated peanut agglutinin (PNA) revealed enhanced binding of the lectin to the patient cells (data not shown). Since PNA binds specifically to galactose-b-(1-3)-N-acetylgalactosamine O-glycans, our result pointed to an O-glycosylation defect in the case of the patient by indicating loss of terminal sialic acid residues that prevents binding of PNA in the case of the control.
Analysis of transferrin-linked N-glycans
To further investigate the transferrin-linked oligosaccharides of the patient, transferrin was purified from control and patient's serum. Oligosaccharides were released with peptide-Nglycosidase F and reductively aminated with the fluorophore 2-AB. Fractionation by HPLC showed that the main glycan peak of the control co-eluted with a 2-AB-GlcNAc 2 Man 3-GlcNAc 2 Gal 2 Neu(N)Ac 2 standard oligosaccharide at 49 min (Fig. 2) . In the case of the patient beyond this full-length complex type N-glycan, several other oligosaccharides eluted earlier (peaks at 29, 34, 39, 41 and 44 min; Fig. 2 Determination of UDP-galactose and CMP-NANA import and measurement of galactose and sialic acid residues transfer Since our findings on transferrin-linked N-glycans mentioned above could be explained by a deficiency of the import of UDPgalactose into the Golgi or by a reduced transfer of galactose residues to the glycoprotein, we determined the import of UDPgalactose and the activity of b-1,4-galactosyltransferase in control and patient-derived fibroblasts. Normal values for the UDP-galactose import (98% + 6) in combination with a slightly decreased activity of b-1,4-galactosyltransferase (76% + 5) were detected for the patient in comparison to the control. Besides, the import of CMP-NANA (70% + 11) and the transfer of sialic acid residues (58% + 4) were decreased (Fig. 3 ).
Western blotting of the COG complex subunits
Since combined N-and O-glycosylation diseases have been described in recent years for different defective subunits of the COG complex, analyses of the expression levels of COG1, COG4, COG5, COG6 and COG7 were performed from the patient fibroblasts and normalized against the expression of control fibroblasts. Equal amounts of protein were used for the assays, as has been proved by b-actin staining. In contrast to COG1 (97% + 5) and COG4 subunits (100% + 2), reduced signals of protein were detected for COG5 (55% + 7), COG6 (21% + 8) and COG7 (62% + 4) in the case of the patient (Fig. 4A ).
Northern blotting
To investigate, if the reduced amount of COG6 detected for the patient in western blotting was due to a decreased translation or successive degradation processes of the COG6-mRNA or due to a reduced expression, we performed northern blot analysis for COG6 and b-actin. In the case of the patient, a reduced signal for COG6 to 16% + 4 was identified in comparison to the control (Fig. 5) , indicating that the decreased amount of COG6 protein was provoked by the instability of the patient's COG6-mRNA and not by degradation of the mutated protein.
Hybridization with a probe specific for b-actin showed that equal amounts of the control and the patient's total RNA were used for the test. Since western and northern blot analyses both hint at a deficiency of COG6 or of one of the other subunits in the respective COG complex lobe in the case of the patient, further investigations were performed by mutational analyses on RNA and DNA levels.
Genetic analysis
In the case of the patient, sequencing analyses of the cDNAs for COG5, COG7 and COG8 were negative. Sequencing analysis of the COG6-cDNA revealed in the case of the patient a homozygous mutation (c.G1646T), leading to amino acid exchange p.G549V in the COG6 protein. Sequence analysis of genomic DNA confirmed the mutational status of the patient. In 100 control alleles, this mutation has not been found (data not shown).
Gel filtration chromatography
To further investigate a potential impact of mutation p.G549V on the constitution of the COG complex, cell lysates of control and patient-derived fibroblasts were separated by gel filtration chromatography, fractionated and subsequently analysed by western blot with an antibody against COG4. In the case of the control, signals for the COG4 antibody were mainly detected in fractions 15 -20, corresponding to a mass of 800 kDa, which would match the entire COG complex. Additional signals were observed from fraction 25 to fraction 34 that became weaker with time. Strong signals in fractions 26 and 27 (upper band) were due to unspecific binding of the antibody. In the case of the patient fibroblasts, signals were detected throughout fractions 15-34 when incubated with the COG4 antibody. In contrast to the control, the patient showed more signals in fractions of smaller masses (Fig. 4B) .
Complementation of COG6 deficiency in CDG-IIL fibroblasts
In order to confirm the deficiency of COG6 as cause for the glycosylation defect of our patient, we expressed the wild-type COG6-cDNA in patient's fibroblasts, utilizing retroviral gene transfer. As a control, we investigated whether the retroviral vector alone affects the functionality of the COG complex in the patient-derived fibroblasts by retrograde protein transport studies after Brefeldin A (BFA) treatment. BFA is widely used to investigate the function of the Golgi apparatus and the mechanisms regulating membrane trafficking in different cell types.
By reversible interaction with the GDP/GTP-exchange factor, BFA inhibits the activation of ADP-ribosylation factor 1, and thereby interfering with elementary procedures in the Golgi. Moreover, BFA inhibits the formation of COPI vesicles on the Golgi apparatus, necessary for the anterograde protein transport. Since the retrograde transport of proteins is not affected by BFA treatment, incubation with BFA leads to a rapid relocation of Golgi proteins into the endoplasmic reticulum and subsequently to the disorganization of Golgi compartments (16) . As in cases of different COG deficiencies, a significant delay in the breakdown of Golgi compartments was noticed after BFA treatment, fibroblasts of a control and our patient were incubated with BFA for different periods (0-15 min) and analysed for their Golgi structures by immunofluorescence studies with the Golgi marker GM130 ( Fig. 6A -P) after proving that GM130 and COG4 co-localize (data not shown). Quantification of control and patient's fibroblasts was performed by analysing the ER staining pattern of 300 cells at different time points, respectively (Table 1) . Nontransduced control (Fig. 6A) and patient-derived fibroblasts (Fig. 6E) as well as mock-transduced (Fig. 6I) and wild-type COG6-transduced fibroblasts (Fig. 6M) of the patient showed the localization of GM130 in all cisterns of the Golgi apparatus at time point 0 min. In the case of the control, degradation of the Golgi compartments was completed after 5 min incubation with BFA (Fig. 6B) , where in the case of the non-transduced (Fig. 6H ) and mock-transduced (Fig. 6L) fibroblasts of the patient, the same effect was not visible before 15 min. After retroviral transduction of patient-derived fibroblasts with wild-type COG6-cDNA, a 5-min incubation with BFA was sufficient for a nearly complete redistribution of Golgi proteins and therefore comparable to the non-transduced control (Fig. 6N ).
DISCUSSION
In a patient who presented clinically with a multi-organic phenotype characterized by intractable focal seizures, vomiting and loss of consciousness due to intracranial bleedings and death in early infancy, we identified the deficiency of COG6 complex as a molecular cause for her disease.
Initial diagnostics for the glycosylation state of the patient's serum transferrin led to a characteristic CDG-II pattern. The result was confirmed by IEF of the alternative marker protein a-1-antitrypsin as well as by western blot analysis of serum transferrin. Investigation of ApoCIII by IEF further showed that also core 1 mucin-type O-glycans were affected in the case of the patient, which accordingly led to an enhanced staining pattern with lectin PNA. The data clearly indicated a generalized defect in protein N-and Oglycosylation. Since mass spectrometric investigations of the patient's transferrin bound N-glycans additionally revealed a decrease in galactosylation and sialylation with all forms from agalacto-(2-AB-GlcNAc 2 Man 3 GlcNAc 2 ) to disialotransferrin (2-AB-GlcNAc 2 Man 3 GlcNAc 2 Gal 2 Neu(N)Ac 2 ) combined with the reduced activities of UDP-galactose and CMP-NANA transporters as well as of b1,4GalT1 and ST3GalTI glycosyltransferases, our data indicated comparability in essential biochemical hallmarks known for the COG complex diseases (6) . To date, five defects in different subunits of the COG complex have been associated with CDG: COG7 (12), COG1 (13), COG8 (14, 15) , COG4 (7) and COG5 (8) . The clinical picture of the COG defects ranges from mildly (in the case of COG5) to severely affected with death in early infancy (in the case of COG7 and COG6). Nevertheless, due to the small amount of COG patients identified so far, the informative value is still limited. In general, these patients suffer from growth retardation, failure to Figure 5 . Northern blot analysis for COG6. Total RNA was isolated from a control and the patient and hybridized with a COG6-specific probe. Subsequently, hybridization with a probe specific for b-actin was performed to normalize the data. thrive, hypotonia, microcephaly and cerebral atrophy, features which are also known from other glycosylation deficiencies of CDG-I and CDG-II.
Besides the biochemical characteristics mentioned above, COG patients show instability of their affected COG complex subunit(s). Hence, we analysed the steady-state levels of the COG proteins of our patient by western blotting and found clearly reduced amounts of the patient's COG6 (minus 78%), COG5 (minus 44%) and COG7 (minus 38%) in comparison to the control, assuming an affection of its COG complex lobe B. This is consistent with recent findings in other COG patients, where mutations in one of the COG subunits caused protein instability which was always accompanied by reduced expression of at least one other subunit of the respective lobe. Sequencing analyses of COG5-to COG8-cDNAs revealed a homozygous mutation (c.G1646T) in the COG6-cDNA of the patient that caused amino acid exchange p.G549V. In contrast to other COG patients, this mutation did not lead to reduced amounts of COG6 by protein instability or degradation, rather instability of the patient's COG6-mRNA occurred, as has been demonstrated by northern blot analysis. By gel filtration chromatography combined with western blotting for the detection of subunit COG4, we investigated the effect of the reduced COG6 level on the patient's COG complex structure (Fig. 4B) . Main signals were detected in fractions 15 -20 in the case of the control, indicating the presence of the entire COG complex with a size of 800 kDa. Further diminishing signals with masses between protein standards thyroglobulin (669 kDa) and aldolase (158 kDa) were observed from fraction 25 on, which could be explained by the existence of COG subcomplexes (e.g. COG1 to COG4 plus COG8 with a mass of 460 kDa or COG5 to COG8 with a mass of 340 kDa), since similar effects were also observed in different COGdeficient mammalian cell lines (17) . In the case of the patient, signals indicating the full COG complex were seen in fractions 15 -20, leading to the assumption that the mutated COG6 subunit allows for the assembly of the complete COG complex. Nevertheless, in contrast to the control, more signals in fractions 21 -34 in the patient-derived fibroblasts with masses smaller than 700 kDa were detected, which might be ascribed to the accumulations of COG subcomplexes. As also signals in fractions 32 -34 were observed, there is incidence for the existence of subunit COG4 with another subunit of lobe A or with COG1 as Figure 6 . BFA assay. Fibroblasts of a control (non-transduced, A-D) and the patient (non-transduced, E-H; mock-transduced, I-L; wild-type COG6 transduced, M-P) were incubated for different periods (0 -15 min) with BFA. Cells were fixed and analysed by immunofluorescence for localization of Golgi marker GM130 (green). The cell nucleus (blue) was stained with DAPI. Bar: 10 mm.
well as COG4 protein on its own, suggesting a complete breakdown of the patient's COG complex in part. If this was due to the decrease in the steady-state level of COG6 protein in combination with down-regulations of its partners COG5 and COG7, which might result in a lower association of all subunits with the Golgi compartments or due to a direct impact of mutation p.G549V on the patient's COG complex structure itself, remains to be solved. However, glycine 549 seems to play an important role in COG6 function, since it is a highly conserved amino acid residue in COG6 proteins from yeast to man. To find out if functionality of the patient's COG complex is affected, BFA treatment was performed. As has been demonstrated for deficiencies of COG7 (18), COG8 (14, 15) , COG4 (7) and COG5 (8), treatment of the respective patient cells with BFA led to a prolonged disintegration of the patients Golgi compartments. In the case of our patient, BFA treatment of the fibroblasts led to a 3-fold time delay in retrograde transport of Golgi-resident proteins in comparison to the control, evidencing a malfunction of the patient's COG complex. After retroviral transduction of the wild-type COG6-cDNA into the patient's cells, functionality of its COG complex could be reassembled to a control-like rate, whereas transduction with the empty vector (mock) led to no effect, proving that the depletion of subunit COG6 was disease-causing in our patient.
Recent experiments from yeast presumed that the deletion of SEC37, the corresponding subunit to human COG6, neither interferes with cell growth nor indicates that the association of the COG core proteins (COG1 -COG4) has been affected (19, 20) which is consistent with data from Caenorhabditis elegans where mutations in the COG subunits of lobe A lead to a more severe phenotype than those occurring in lobe B of the C. elegans complex (9). After identification of a disease-causing mutation in subunit COG7 (12), the COG6 deficiency described here is the second defect with fatal outcome after a few weeks of life. Since both subunits are the members of the COG complex lobe B, the allocation of essential and non-essential subunits of the human COG complex is therefore not compatible with the dispositions of subunits from the COG complexes of other species. As also deficiencies of COG2 and COG3 of lobe A have to be identified in patients, the concluding consideration on the role of the different human COG complex subunits remains to be solved.
MATERIALS AND METHODS
Cell lines and cell culture
Fibroblasts from the index patient and controls were maintained at 378C under 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM, Invitrogen), which contained 10% fetal calf serum (FCS; PAN Biotech GmbH), 50 IU/ml penicillin and 50 mg/ml streptomycin. The ecotropic packaging cell line FNX-Eco (ATCC) and the amphotropic packaging cell line RetroPack PT67 (Clontech) cultured in DMEM containing 1× L-glutamine, 1× Pen/Strep and 10% fetal calf serum (PAN Biotech GmbH), which was heat inactivated at 568C for 30 min, at 378C under 5% CO 2 unless otherwise stated.
Antibodies
For western blot analyses, the primary antibodies rabbit antihuman ApoCIII (Biotrend, Cologne), the COG complex subunits COG1, COG4, COG5, COG6 and COG7 (D. Ungar), human serum transferrin (DakoCytomation) and a-1-antitrypsin (DakoCytomation) were used in dilutions of 1:1000 in PBST (0.1% Tween-20), respectively. Primary antibodies mouse antihuman b-actin (Sigma-Aldrich) and mouse antihuman GM130 (Sigma-Aldrich) were used in dilutions of 1:10 000 in PBST and 1:200 in PBS, respectively. Secondary antibody goat anti-rabbit labelled with horseradish peroxidase (Dianova) was used in a dilution of 1:10 000 in PBST. Fluorochrome-conjugated secondary antibody goat anti-mouse Alexa488 (Invitrogen) for the detection of human GM130 was diluted 1:400 in PBST.
IEF and western blot analyses of serum transferrin
IEF and western blot analyses of serum transferrin were performed as described previously (21) .
IEF of a-1-antitrypsin
IEF of human a-1-antitrypsin was performed as described (22) .
IEF of ApoCIII
IEF of ApoCIII was performed as described (23) .
Neuraminidase treatment
Desialylation of glycopeptides of a control and the patient was performed with two different neuraminidases, respectively. 2,3-neuraminidase (Takara) cuts sialic acid residues attached to galactose residues in 2,3 orientation, whereas neuraminidase isolated from Vibrio cholerae (Roche) cuts 2,6-linked sialic acid residues from N-acetylgalactosamine acids and 2,3-linked sialic acids residues from galactose residues. For the assay 12.5 ml serum, 2.5 ml of 1 M NaAc (pH 5.0), 9.5 ml water and 1 ml (0.01 U) of the respective enzyme were incubated at 378C for 4 h. One microlitre was used for IEF of ApoCIII. 
Analysis of transferrin-linked N-glycans
Oligosaccharide moieties of a control and the patient's serum transferrin were isolated, purified and analysed by mass spectrometry on a Bruker Ultraflex TOF/TOF as described previously (24) .
Histochemical staining with PNA
Control and patient-derived fibroblasts were stained with 2 mg/ ml biotinylated PNA (Vector Laboratories) in PBS/1% BSA (Sigma-Aldrich) as described (25) .
Analysis of UDP-[6- The activity of the UDP-galactose:N-acetylglucosamine b-1,4-galactosyltransferase I (b1,4GalTI) was determined as described (24) . Activity of the CMP-N-acetylneuraminateb-galactosamide-a-2,3-sialyltransferase (ST3GalTI) was determined analogous to the b1,4GalTI measurement by following the transfer of 0.06 mCi CMP-[ 
Western blot analyses of the COG subunits
Patient and control fibroblasts were lysed in TBS/1% Triton X-100/protease inhibitor mix (Serva) for 30 min on ice, followed by sonification and vortexing. After centrifugation (16 100 g, 48C for 20 min), 30 mg protein of the supernatant was separated on a denaturing 10% SDS -polyacrylamide gel and transferred onto a nitrocellulose membrane by semi-dry western blotting. The membrane was blocked with 5% milk powder in PBST for 1 h at room temperature (RT) and incubated with antibodies against COG1, COG4, COG5, COG6 and COG7 as well as against b-actin in PBST overnight at 48C. The membrane was washed three times with PBST for 20 min at RT and incubated with the secondary HRP-coupled antibody for 1 h at RT. After washing, visualization was performed by adding chemiluminescent reagent (Pierce).
Sequencing analyses
Total RNA was extracted from controls and patient-derived fibroblasts using the RNAeasy kit (Qiagen). First-strand cDNA was synthesized from 0.5 mg of total RNA with Omniscript reverse transcriptase (Qiagen) and primer COG6-R1. COG6 cDNA was amplified with primers COG6-F1 and COG6-R1 with the HotStar-Taq-Polymerase kit (Qiagen) with a preincubation at 958C for 15 min followed by 30 cycles with 1 min at 948C, 0.5 min at 558C and 4 min at 728C. The nested PCR with 35 cycles was carried out with the primers COG6-F2 and COG6-R2. Reverse transcriptase -PCR products were analysed on 1% agarose gels. PCR fragments were prepared with the QIAquick PCR purification kit (Qiagen) and subcloned into the pGEM-T-easy vector (Promega). Genomic DNA was prepared from control and patient-derived fibroblasts by the standard procedures (27) . In a first round of PCR, exon 2 of the COG6 gene was amplified from 100 ng template with primers COG6-Ex2-F1 and COG6-Ex2-R1 using the Pfu-TurboTaq-Polymerase (Stratagene) with a preincubation at 958C for 1 min followed by 28 cycles with 1 min at 948C, 0.5 min at 558C and 1 min at 728C. Further amplification was carried out with nested primers COG6-Ex2-F2 and COG6-Ex2-R2. PCR products were analysed on a 1% agarose gel, extracted with the QIAquick PCR purification kit (Qiagen). Sequence analysis of PCR products and plasmids was performed by dye-determined cycle sequencing with primers COG6-F2, COG6-F3, COG6-F4, COG6-F5 and COG6-R2 for COG6-cDNA and with COG6-Ex2-F2 and COG6-R2 for exon 2 of COG6 gene on a Applied Biosystems model 373A automated sequencer. Analyses of the COG5-, COG7-and COG8-cDNAs from the patient and controls were performed accordingly to the protocol for COG6 mentioned above. Primers for PCR amplifications and sequencing are listed in Table 2 .
Northern blotting
Northern blotting was carried out for COG6 and b-actin by following the standard procedures (27) with 5 mg of total RNA extracted from controls and patient-derived fibroblasts using the RNAeasy kit (Qiagen). RNA was transferred onto a nylon membrane (Amersham Hybond TM -N + , GE Healthcare). Labelling of the COG6-specific probe (10 ng), amplified with primers COG6-F4 and COG6-R2 or the b-actin probe (10 ng; Roche), was carried out with the 'random prime labelling system' (GE Healthcare) after addition of [a-32 P]dCTP (3000 Ci/mmol; Perkin Elmer) by adhering the manufacturer's guidelines. Hybridization in Amersham Rapid-hyb TM Buffer (GE Healthcare) was accomplished at 708C for 2 h. Washing of the blot was performed in 2× SSC [0.3 M NaCl, 0.03 M Na 3 -citrate with 0.1% (w/v) SDS at 748C for 20 min and 2× 15 min in 0.2× SSC with 0.1% (w/v) SDS at 658C], followed by exposure to an autoradiography film.
Retroviral complementation
Ecotropic FNX-Eco cells (5 × 10 5 ) were seeded onto dishes (60-mm diameter) 1 day before transfection. Transient transfection by FuGENE6 reagent was performed according to the manufacturer's protocol (Roche), with 1 mg of LNCX2 vector (mock), and LNCX2 with the wild-type COG6-cDNA. Further procedures were performed as described elsewhere (28) . The supernatant with the amphotropic retroviral particles was used to transfect patient and control fibroblasts. After infection of fibroblasts, the medium was replaced by DMEM, containing 10% heat-inactivated FCS with 225 mg/ml G418 (Gibco BRL). Selection was carried out for 10 days. GTTCGGAGTCAGCGCCCCTTGT  COG8-F2  GGTCCGGAAGGGAAGTGACG  COG8-F3  CGTGGAGGCGTCGCTCGG  COG8-F4  CGAGATGCTTGGCTCCGGTC  COG8-F5  CCTGTTTTCCAGCGGGTGGC  COG8-R1  CCATCTCGTGCTGGATGATGC  COG8-R2 CCTGTTCTCCATTGGGGTCC
